A prespecified exploratory analysis of this study examined the role of different biomarkers at baseline, including TILs, PD-L1, CD8, HER2 expression and amplification, tumor mutational burden (TMB), effector T-cell gene signature, and PIK3CA mutational status. The gene discussed is ERBB2; the disease is neoplasm.